Research
Hormonal
GLP-1 receptor agonists reduce cardiovascular risk in patients with obesity and established cardiovascular disease, even in the absence of diabetes.
For individuals with obesity and existing heart disease, GLP-1 medications like semaglutide can significantly reduce the risk of major cardiovascular events and promote weight loss, even without diabetes. This makes them a valuable tool for comprehensive heart health management.
StrongSupportsHIGH confidence
The results showed that semaglutide participants had an average weight loss of 10.2% over a four-year period, while the placebo group had an average weight loss of 1.5%. Semaglutide was found to have significant results in this study, not only for lowering weight but also for reducing adverse cardiovascular events.
Why this rating
Based on the large SELECT trial (17,604 participants).
Source
Glucagon-Like Peptide-1 Receptor Agonist Mediated Weight Loss and Diabetes Mellitus Benefits: A Narrative Review
Alan D. Kaye et al. · Cureus · 2024
narrative_reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →